Background: Investigations of the associations with colorectal cancer have yielded conflicting results. The aim of our study was to synthesize the research on colorectal cancer risks in BRCA mutation carriers by means of a systematic review and quantitatively by means of meta-analyses overall and in subgroups of BRCA mutation carriers. Methods: We searched PubMed/MEDLINE, Embase, Cochrane, Scopus, and ProQuest Dissertation & Theses. Unadjusted odds ratios (ORs) were used to derive pooled estimates of colorectal cancer risk overall and in subgroups defined by mutation type (BRCA1 or BRCA2), cancer type (colorectal or colon cancer), study design (age-sex-adjusted or crude), and ascertainment method (ascertained or inferred genotyping). The associations were evaluated using random-effect models. All statistical tests were two-sided. Results: Eighteen studies were included in the systematic review: five cohort studies with ascertained BRCA mutation, six cohort studies involving pedigree analysis, five case-control studies, and two kin-cohort studies. Of these, 14 were used in the metaanalysis, which revealed a statistically significant increased risk of colorectal cancer in overall BRCA mutation carriers (OR ¼ 1.24, 95% confidence interval (CI) ¼ 1.02 to 1.51, P ¼ .03). In subgroup meta-analyses by BRCA type, BRCA1 mutation was associated with increased risk of colorectal cancer (OR ¼ 1.49, 95% CI ¼ 1.19 to 1.85, P < .001), but BRCA2 was not (OR ¼ 1.10, 95% CI ¼ 0.77 to 1.58, P ¼ .61). In subgroup meta-analyses of studies reporting estimates adjusted for age and sex, an increased risk of colorectal cancer for BRCA1 (OR ¼ 1.56, 95% CI ¼ 1.23 to 1.98, P < .001), but not for BRCA2 (OR ¼ 1.09, 95% CI ¼ 0.75 to 1.58, P ¼ .66) was observed. Analyses stratified by ascertainment method found no association between BRCA mutation and colorectal cancer risk.
mutation carriers to be 4.11 (95% confidence interval [CI] ¼ 2.36 to 7.15) (14) . Other studies reported the risk of developing colorectal cancer in relatives of familial breast cancer patients to be higher than in the general population (15, 16) . However, studies on the incidence of colorectal cancer in BRCA mutation carriers have shown contradictory results, and generalizable estimates of the magnitude of the risk of colorectal cancer in BRCA mutation carriers remain lacking. A qualitative appraisal and narrative review by Sopik et al. (17) concluded that an increased risk of colorectal cancer exists in high-risk families and that the risk is limited to BRCA1 mutation carriers younger than age 50 years. Hence, the purpose of our study was to synthesize the research on colorectal cancer risks in BRCA mutation carriers, qualitatively by means of a systematic review and quantitatively by means of overall and stratified meta-analyses.
Materials and Methods
We followed the guidelines summarized in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (18) and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) (19) statements. The full checklists summarizing compliance with both PRISMA and MOOSE are included in the Supplementary Materials (available online).
Study Selection
The following modified participants, interventions, comparators, outcomes, and studies approach (PICOS) guided eligibility screening of studies for inclusion in our study: 1) Participants: human adult participants (older than age 18 years) who tested positive for either BRCA1 or BRCA2 mutations or had a familial risk of BRCA mutation; 2) Intervention: not applicable; 3) Comparisons: cancer-affected and cancer-unaffected BRCA mutation carriers vs population-based incidence rates, and BRCAnegative cancer-affected patients; 4) Outcomes: incidence or prevalence of colorectal cancer, including colon cancer if differentiated; 5) Studies: investigations reporting colorectal cancer incidence data or sufficient data to calculate risk. Excluded were editorials, letters, commentaries, and review papers; publications reporting diseases other than colorectal cancer, such as Lynch syndrome, familial adenomatous polyposis, PeutzJeghers syndrome, or Cowden syndrome; and studies without colorectal cancer incidence data or with insufficient data to calculate risk.
Data Sources
A professional health science librarian (JM) supported the search of the following bibliographic databases: PubMed/ MEDLINE , Embase (1947 Embase ( -2017 , Cochrane Library (1898-2017), and ProQuest Dissertations & Theses (1861-2017). The search was executed by two of the investigators (MO, SY) and included a combination of indexing terms (MeSH terms in PubMed and EMTREE terms in Embase) as well as keyword terms including "Genes, BRCA1," "Genes, BRCA2," and "Colorectal Neoplasms" and translated for each database. We also conducted a manual check of the reference list of key articles for the recent relevant publications through Scopus (1823-2017). The search strategy is included as Supplementary Table 1 , available online.
Data Extraction
Two reviewers (MO, IA) independently screened article titles and abstracts for eligibility. Disagreements were resolved through discussion and consensus, with unresolved issues escalated to a third person (AM). The following information was retrieved from each study using a predeveloped worksheet: publication date, location, study design, type of colorectal cancer, description of cases and controls (eg, number, recruitment method, matching, etc.), age and sex of cases and controls, and risk estimates with corresponding 95% CIs. Authors of each trial were contacted for additional information if needed.
Quality Assessment
Quality assessment was performed on each included study by two reviewers (MO, IA) independently using the NewcastleOttawa Scale (NOS). The NOS consists of eight items focused on three domains: selection of study groups, ascertainment of the exposure and outcome, and comparability of groups to assess the quality of observational studies. Ratings were based on a star system and studies with a maximum rating of nine. Studies with one to three stars were categorized as low quality, four to six stars categorized as moderate quality, and seven to nine stars categorized as high quality.
Summary Measures
To quantify the risk of colorectal cancer in the meta-analysis, we used the unadjusted odds ratio as the common metric for studies that reported an estimate such as relative risk, odds ratio, standardized incidence ratio (SIR), hazard ratio (HR), or provided sufficient information to compute the risk estimate. The unadjusted (crude) odds ratio (OR) for each study was calculated from a 2 Â 2 contingency table created for each study. This calculated OR was used in the meta-analysis including all subgroup meta-analyses. The cohort studies that reported the SIR and case-control studies that adjusted for age and sex were used in subgroup meta-analyses to provide age-and sexadjusted estimates.
Statistical Analyses
Meta-analytic calculations were performed using Comprehensive Meta-Analysis (v. 3.0). Study-specific relative log OR were weighted by the inverse of their variance to calculate a summary estimate and the corresponding 95% CIs. Assuming varying effect sizes across studies, associations between BRCA gene mutational status and OR was evaluated using DerSimonian and Laird random-effect models. The Cochran Q statistic was used to measure heterogeneity through a weighted sum of squares; and the
to quantify the total percentage of variation across each study due to heterogeneity. A P value lower than .05 for the Cochran Q test and I 2 exceeding 50% were used as a cutoff for statistically significant heterogeneity (20) . Publication bias was presented by using a contour-enhanced funnel plot of standard error against the effect estimate. The Egger linear regression test method was applied to evaluate asymmetry of the funnel plot and a statistically significant publication bias was considered when the P value was less than .10. Due to the limited number of studies in the overall and subgroup meta-analyses, statistical tests REVIEW comparing the summary effect measures (odds and risk ratio) was not performed,
Subgroup Analyses
Due to the expected heterogeneity, prespecified subgroup metaanalyses were conducted as shown in Figure 1 . After stratifying by BRCA1 and BRCA2, we explored study design features (eg, ascertained vs inferred genotyping; colorectal cancer vs colon cancer; age-sex adjusted vs crude) as sources of heterogeneity.
Results

Study Selection
Our initial literature search yielded a total of 442 relevant abstracts from PubMed, 616 relevant abstracts from Embase, and 12 relevant abstracts from Cochrane Library (Figure 2 ). An additional 12 records were identified by reviewing the reference lists of articles retrieved in the Scopus search or known to the authors. ProQuest was searched for theses and dissertations and none were found. After removing duplicates, 949 records were screened. A total of 917 publications were excluded based on abstracts review, leaving 32 publications assessed in full text. Of these, 14 were excluded: 10 publications did not include an incidence rate for colorectal cancer, one was an editorial, one study was a review paper, and two publications did not include information on BRCA mutation. A total of 18 separate studies were retained for the systematic review. Four of these studies were omitted from the meta-analysis: two did not include sufficient statistical information to compute an effect size, and two were kin-cohort studies using frequency of family history of colorectal cancer as an outcome.
Systematic Review
Study Characteristics
Of the 18 studies in the systematic review, five were cohort studies with ascertained BRCA mutation carriers, six were cohort studies involving pedigree analysis, five were case-control studies, and two were kin-cohort studies. These studies are summarized in Table 1 .
Cohort Studies With Ascertained BRCA Mutation Carriers (n 5 5) 11.30) , indicating that BRCA1 but not BRCA2 mutation carriers had a statistically significant higher colorectal cancer risk than noncarriers. Thompson and Easton (11) reviewed data from 699 families with at least one known BRCA1 mutation carrier from 30 centers across Europe and North America. Of the 11 847 subjects, 2245 were BRCA1 mutation carriers, 1106 were noncarriers, and 8496 individuals had not been tested for mutations. The colorectal cancer incidence rate in the 2245 BRCA1 mutation carriers was used to estimate relative risk. Fourteen cases of colon cancer were screened among BRCA1 mutation carriers, compared with 7.36 expected cases from the SEER incidence rates for Caucasians (1983) (1984) (1985) (1986) (1987) , yielding a statistically significant relative risk for colon cancer in BRCA1 carriers of 2.03 (95% CI ¼ 1.45 to 2.85). In addition, in the 8496 family members not tested for BRCA mutations, 76 cases of colon cancer were found compared to 48.77 expected cancers, resulting in a statistically significant SIR of 1.46 (95% CI ¼ 1.24 to 1.94).
In a cohort study, Lin et al. (24) compared the lifetime colorectal cancer risk in BRCA mutation carriers relative to the general population. The Creighton Hereditary Cancer Institute Registry and the Creighton University Tumor Registry identified 164 BRCA1 and 88 BRCA2 gene mutation carriers and compared their colorectal cancer risk with the lifetime risk from the SEER Cancer Statistics Review (1993) (1994) (1995) . The risk in female and male BRCA mutation carriers was 3.2% and 5.6%, respectively; which was statistically not significantly different from the corresponding 5.9% and 6.0% risks in the general female and male populations.
Summarized, in this set of five cohort studies with ascertained BRCA mutation carriers, two studies reported an increased risk of colon and colorectal cancer among BRCA1 mutation carriers. The remaining studies, all of which included both BRCA1 and BRCA2 carriers and focused on colorectal Records idenƟfied through database searches of PubMed (n=442), Embase (n=616), and Cochrane Library (n=12)
AddiƟonal records idenƟfied through citaƟon search (n=12)
Records aŌer duplicates removed (n=949)
Full-text arƟcles assessed for eligibility (n=32)
Records excluded (n=917)
Full-text arƟcles excluded (n=14):
No incidence rate for colorectal cancer (n=10), editorial (n=1), review paper (n=1), and no informaƟon on BRCA mutaƟon (n=2) Studies included in systemaƟc review (n=18)
Studies included in quanƟtaƟve synthesis
(meta-analysis) (n=14)
Studies excluded (n=4):
Insufficient staƟsƟcal informaƟon to compute an effect size (n=2) and kincohort studies (n=2) Figure 2 . Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Table 1 (Table 1) . Pedigrees were drawn for all members, and the youngest typed carrier and his/her first-degree relatives were selected for the cohort. These presumed BRCA1 or BRCA2 mutation carriers comprised 1811 individuals, including 1008 women (55.6%) and 803 men (44.3%). The observed number of colon cancers in the carrier group was 20, while 16.5 were expected based on the Netherlands Cancer Statistics (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) , yielding a statistically significant relative risk of 1.50 (95% CI ¼ 0.90 to 2.30) and indicating an increased risk of colorectal cancer in presumed BRCA1 or BRCA2 mutation carriers.
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Brohet et al. (27) reported on part of a nationwide study in the Netherlands of 517 families with the BRCA1 mutation ( Table 1 ). The risk of other cancers was estimated through an assumption of 50% cohort family members being a carrier. These presumed BRCA1 mutation carriers comprised 6585 individuals, including 2843 women (43.2%) and 3742 men (56.8%). The observed number of colon cancers in the BRCA1 mutation carrier group was 93, whereas 53.1 were expected based on the Netherlands Cancer Statistics (1990 Statistics ( -2005 , yielding a statistically significant relative risk of 2.51 (95% CI ¼ 2.02 to 3.07) and indicating an increased risk of colon cancer in presumed BRCA1 mutation carriers.
Brose et al. (28) examined the colon cancer risk in 147 families of patients from a breast cancer risk clinic in the United States ( Table 1 ). The sample of 483 participants included 316 subjects who tested positive for BRCA1 and 167 presumed carriers, which referred to siblings or parents of the identified BRCA1 mutation carriers. The cumulative lifetime colon cancer risk in the 483 BRCA1 mutation carriers was compared with the population colon cancer risk of 5.6% in the SEER data. Nineteen cases of colon cancer (11.0%) were identified among carriers, resulting in a relative risk of 2.00 for colorectal cancer in BRCA1 mutation carriers, but the study did not report confidence intervals and P values.
The Breast Cancer Linkage Consortium (BCLC) (29) examined colon cancer risks in 173 families with BRCA2 mutations. The final cohort comprised 3728 individuals, including 681 individuals with breast or ovarian cancer, 471 unaffected BRCA2 mutation carriers, 390 tested noncarriers, and 1186 individuals (Table 1) . Each family included at least four people with ovarian or breast cancer diagnosed before age 60 years with evidence of linkage to BRCA1 mutation. The incidence of colon cancer in BRCA1 mutation carriers was compared with the expected numbers of colon cancers from the general population using age-and sex-specific incidence rates from SEER for the United States, and England and Wales incidence rates for Europe. There were seven colon cancer cases among the 464 BRCA1 mutation carriers compared with 2.22 expected cases for the general population, yielding a statistically significant relative risk for colon cancer among BRCA1 mutation carriers of 4.11 (95% CI ¼ 2.36 to 7.15).
In summary, in this set of six cohort studies involving pedigree analysis, four studies reported no increased risk of colon cancer among BRCA1 or BRCA2 mutation carriers and one study reported no increased risk of colorectal cancer among BRCA1 or BRCA2 mutation carriers. The remaining one study showed an increased risk of colon cancer among BRCA1 mutation carriers. (Table 1 ). In the case group, six BRCA1 or BRCA2 mutation carriers were identified compared with 118 BRCA1 or BRCA2 mutation carriers among control subjects. Among these six carriers, two were 185delAG carriers, one was a 5382insC carrier, and three were 6147delT carriers. This yielded an unadjusted OR of 0.50 (95% CI ¼ 0.22 to 1.14), which was statistically nonsignificant and indicates no increased risk of colorectal cancer in the BRCA1 or BRCA2 mutation carriers.
Niell et al. (32) Chen-Shtoyerman et al. (33) screened 225 unselected Ashkenazi Jewish colorectal cancer patients for BRCA1 or BRCA2 mutations and compared them with the mutation frequency in the general Ashkenazi Jewish population of 5318 without colorectal cancer (Table 1) . Four carriers were identified (1.8%), which was not statistically significantly different from the 120 carriers from the general Ashkenazi Jewish population (2.3%). Among these four carriers, one was a 185delAG carrier, one was a 5382insC carrier, and two were 6147delT carriers. As the study did not report ORs, confidence intervals, and P values, the unadjusted OR was calculated to be 0.78 (95% CI ¼ 0.29 to 2.14), which was not statistically significant and indicates no increased risk of colorectal cancer in the BRCA1 or BRCA2 mutation carriers.
In a preliminary study, Drucker et al. (34) screened 136 Israeli Jewish colorectal cancer patients for BRCA1 or BRCA2 mutations and compared Ashkenazi to non-Ashkenazi, but did not report statistical results beyond counts and rates (Table 1) . Among Ashkenazi Jews, 3 of 87 (3.5%) carriers had colorectal cancer, whereas no carriers were found among 49 non-Ashkenazi Jews, indicating a possible elevated risk of BRCA mutation in Ashkenazi compared to non-Ashkenazi colorectal cancer patients.
Summarized, in this set of five case-control studies, three studies reported no increased risk of colorectal cancer among BRCA1 or BRCA2 mutation carriers and one study reported no increased risk of colorectal cancer among BRCA1 mutation carriers. The remaining study was a preliminary descriptive study showing a possible increased colorectal cancer risk in Ashkenazi Jews. The two studies reporting a subgroup analysis for early-onset colorectal cancer did not infer an age-related risk.
Cohort Studies Involving Kindred (n 5 2)
Risch et al. (35) screened 649 unselected incident cases of ovarian cancer diagnosed in Ontario, Canada, during 1995-1996 for mutations in BRCA1 and BRCA2. Of the 515 women with invasive ovarian cancer, 60 had a BRCA mutation, including 39 with BRCA1 and 21 with BRCA2. Family histories of colorectal cancer were compared in mutation carriers and noncarriers. The incidence rate of colorectal cancer among first-degree relatives was compared with the incidence rate for 455 noncarriers from unselected ovarian cancer cases. A total of 2.9% incidence were observed among BRCA1 and 10.3% among BRCA2 carriers compared to 4.2% expected in the comparison group. The relative risk of colorectal cancer for BRCA1 mutation carriers was 0.70 (95% CI ¼ 0.17 to 2.80), which was statistically nonsignificant, indicating no increased risk of colorectal cancer among first-degree relatives of the BRCA1 mutation carriers. However, for BRCA2 mutation carriers, the relative risk was 2.50 (95% CI ¼ 1.00 to 6.30), which was statistically significant (Table 1) .
Struewing et al. (36) screened 5318 Ashkenazi Jewish volunteers for BRCA1 and BRCA2 mutations and compared family histories of colon cancer in 114 BRCA mutation carriers and 4759 noncarriers (Table 1) . Nine (7.8%) colon cancer family history cases were reported in the BRCA carriers and 509 (10.6%) in the noncarriers group. As relative risk, confidence interval, and P value were not reported, we estimated the relative risk to be 0.71 (95% CI ¼ 0.36 to 1.42), which was not statistically significant and indicated no increased risk of colorectal cancer family histories in the BRCA mutation carriers. Summarized, the two kin-cohort studies reported no increased risk of colorectal or colon cancer family histories among BRCA1 mutation carriers. One study showed an increased risk of colorectal cancer family history among BRCA2 mutation carriers.
Meta-analyses
Fourteen of the 18 studies in the systematic review were included in the meta-analysis. Two studies (24, 34) were excluded, as they had insufficient statistical information to compute an effect size, as were two kin-cohort studies (35, 36) because the outcome was the frequency of a family history of colorectal cancer. All studies included in the meta-analysis had moderate quality (NOS ¼ 4-6) based on the Newcastle-Ottawa Scale quality assessment (Table 1 ). The overall meta-analysis (Figure 3 ) of 18 assessments of colorectal cancer risk in BRCA1 or BRCA2 mutation carriers found a statistically significant increase in the odds of colorectal cancer for BRCA carriers using a randomeffects model (OR ¼ 1.24, 95% CI ¼ 1.02 to 1.51, P ¼ .03).
Four subgroup meta-analyses that focused on only BRCA1 were performed. The first subgroup meta-analysis included the 10 studies that focused on BRCA1 ( Figure 4A ) and found that BRCA1 mutation carriers were at higher risk of colorectal cancer (OR ¼ 1.49, 95% CI ¼ 1.19 to 1.85, P < .001). The second subgroup meta-analysis by BRCA1 only included the seven cohort studies that reported age-and sex-adjusted estimates ( Figure 5A ), and yielded a statistically significant risk of colorectal cancer (OR ¼ 1.56, 95% CI ¼ 1.23 to 1.98, P < .001). The third subgroup meta-analysis included four studies that screened for colon cancer and focused on BRCA1 (Supplementary Figure 1A , available online). There was a statistically significant difference in risk of colorectal cancer for BRCA1 carriers (OR ¼ 1.85, 95% CI ¼ 1.39 to 2.47, P < .001). The fourth subgroup meta-analysis included four studies that ascertained the BRCA mutation and focused on BRCA1 ( Supplementary Figure 2A, available online) . There was no statistically significant difference in the risk of colorectal cancer for BRCA1 carriers (OR ¼ 1.20, 95% CI ¼ 0.85 to 1.71, P ¼ .31).
Four subgroup meta-analyses that focused on BRCA2 only were performed. The first subgroup meta-analysis of seven studies focused on BRCA2 ( Figure 4B ) found no statistically significant risk of colorectal cancer for mutation carriers (OR ¼ 1.10, 95% CI ¼ 0.77 to 1.58, P ¼ .61). The second subgroup meta-analysis by BRCA2 only included the cohort studies that reported age-and sex-adjusted estimates. The analysis of six studies ( Figure 5B ) revealed no statistically significant risk of colorectal cancer between carriers and noncarriers (OR ¼ 1.09, 95% CI ¼ 0.75 to 1.58, P ¼ .66). The third subgroup meta-analysis of two studies that screened for colon cancer and focused on BRCA2 (Supplementary Figure 1B, available online) found no statistically significant risk of colorectal cancer for BRCA2 carriers (OR ¼ 1.22, 95% CI ¼ 0.70 to 2.12, P ¼ .49). Lastly, a subgroup meta-analysis of three studies that ascertained BRCA mutation and focused on BRCA2 (Supplementary Figure 2B , available online) found no statistically significant risk of colorectal cancer for BRCA2 carriers (OR ¼ 1.02, 95% CI ¼ 0.58 to 1.82, P ¼ .94).
The contour-enhanced funnel plot of standard error by effect estimate (Figure 6 ) showed, in general, symmetry. Coupled with the Egger test (P ¼ .17) indicating symmetry in the funnel plot, there was no evidence of publication bias in the studies included in the meta-analysis.
Discussion
The principal finding of our systematic review of 18 and metaanalysis of 14 studies is that the risk of colorectal cancer is Figure 3 . Forest plot of the association between overall BRCA mutation carriers and colorectal cancer risk expressed as unadjusted odds ratio. Squares indicate studyspecific risk estimates; horizontal lines indicate 95% confidence intervals (CI); diamond indicates summary estimate with the corresponding 95% CI. DerSimonian and Laird random-effects model was used and all statistical tests were two-sided. Test for heterogeneity:
moderately elevated in BRCA1 but not in BRCA2 mutation carriers. This increased risk was independent of study design, specific cancer type, ascertainment method, or age. These findings are quite different from those reported by Sopik et al. (17) in a narrative review of, by their classification, four cohort studies, five case-control studies, and four pedigree studies. These authors concluded that there may be an increased risk for colorectal cancer in BRCA1 or BRCA2 mutation carriers from high-risk families, but that there is little evidence of such risk in unselected populations with founder mutations. Further, the Phelan et al. (22) prospective study of 7015 women with BRCA1 and BRCA2 mutations included in the Sopik et al. (17) review found no colorectal cancer risk signal in the sample at large, but a 4.76-fold increase in risk in women aged 30-49 years carrying the BRCA1 mutation (within a 95% CI margin indicating a 2.21-fold to ninefold incremental risk) (22) .
Especially the findings from our meta-analyses provide additional insights into the association of BRCA1 and BRCA2 genotypes and colorectal cancer risk. We detected a statistically significant signal in colorectal risk when considering both BRCA1 and BRCA2 studies. However, our results showed that if there is an increased risk for colorectal cancer, it is among BRCA1 mutation carriers and not among BRCA2 mutation carriers. These findings were not a function of study design for BRCA2: whether examining through studies that reported ageand sex-adjusted estimates, focused on colon cancer, or ascertained BRCA2 carriers. BRCA1 showed a statistically significant risk signal for colorectal cancer with a higher estimates for subgroup analysis through age-and sex-adjusted estimates, and colon cancer. However, the results were not statistically significant for subgroup analysis when including only ascertained BRCA1 carriers. The conflicting results for BRCA1 among subgroups may be due to an inherent bias of pedigree-based studies, as these do not adjust for ascertainment bias. To reduce ascertainment bias, there are strategies to modify segregation analysis and condition on the ascertainment of the proband. However, the pedigree-based studies included in the metaanalysis did not use this statistical method. Note that, as explained in the Methods section, we did not perform statistical comparisons between summary effect measures because of the limited number of studies in the meta-analysis and the associated lack of statistical power. For instance, to compare BRCA1 vs BRCA2 studies on pedigree vs nonpedigree studies, the relative lack of statistical power (10 BRCA1 and 7 BRCA2 studies; 6 pedigree and 8 nonpedigree studies) would have increased the likelihood of type II errors and false-negative findings.
Both BRCA1 and BRCA2 work in a common pathway of genome protection known to function in homologous recombination. However, the two proteins work at different stages in the BRCA1-and BRCA2-mediated homologous recombination pathway. The BRCA1 functions upstream of BRCA2; therefore, the function of BRCA2 is dependent on BRCA1. Also, BRCA1 functions in both checkpoint activation and DNA repair, whereas BRCA2 is a mediator of the core mechanism of homologous recombination (37) . The links between the two proteins are not well understood, but the difference in mechanism might explain why BRCA1 but not BRCA2 is associated with an increased risk for colorectal cancer. DerSimonian and Laird random-effects model was used and all statistical tests were two-sided. Test for heterogeneity:
Our findings contribute to the evolving knowledge base about the association of BRCA1 and BRCA2 mutation status and the risk for certain cancers. Table 2 presents the results from previous meta-analyses for breast, ovarian, and prostate cancer, pancreatic cancer, as well as our results in colorectal cancer as reported herein. The association is well established for breast and ovarian cancer and examining for BRCA mutations has been routine practice. The association of BRCA mutations with the risk of developing cancer for less established cancer, such as prostate cancer, colorectal cancer, and pancreatic cancer, show relatively lower risk and with conflicting results. A metaanalysis of prostate cancer showed no association between BRCA1 mutation and cancer risk. Although many other studies showed statistical association for BRCA2 (11, 21, 25) , no metaanalysis has been reported for the association between BRCA2 mutation and prostate cancer. For pancreatic cancer, there is no meta-analysis evidence of studies on the risk associated with BRCA1 and/or BRCA2. However, studies (25, 40, 41) have shown that BRCA mutations contribute to a higher risk of pancreatic cancer, with relative risk ranging from 2.11 to 5.79 for BRCA2 and 0.80 to 4.11 for BRCA1. Our meta-analyses provide evidence of increased risk of colorectal cancer for BRCA1 and can be further used in the polygenic risk for personalized colorectal cancer screening.
We could not meta-analytically validate the risk of early-onset colorectal cancer risk in BRCA1 carriers, which was perhaps the major conclusion for the previous Sopik et al. (17) study, as the only evidence is from the Phelan et al. (22) subanalysis. This remains a hypothesis to be further investigated, especially considering a clinical challenge of this finding by Evans et al. (42) . Of the eight colorectal cancers in the BRCA1-positive women younger than 50 years, only four were confirmed in the Phelan et al. (22) analysis. Of these, two were squamous cell carcinomas of the anus, which Evans et al. (38) attribute to human papilloma virus. The two confirmed colorectal adenocarcinomas were similar to the expected number of 1.68 cases. Evans et al. also reviewed their own data on 890 women with a BRCA1 mutation, of whom 592 were less than age 50 years. One case of colorectal cancer occurred among those younger than age 50 years. There were no cases of colorectal cancer among BRCA2. Squares indicate study-specific risk estimates; horizontal lines indicate 95% confidence intervals (CI); diamond indicates summary estimate with the corresponding 95% CI. DerSimonian and Laird random-effects model was used and all statistical tests were two-sided. Test for heterogeneity: 
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women older than age 50 years, whereas 3.78 cancers would have been expected.
Further, our quantitative meta-analysis results from 14 studies differ from the qualitative interpretations by Sopik et al. (17) of 13 studies. Our data provide compelling evidence of an increased risk of colorectal cancer in carriers of the BRCA1 mutation, but not carriers of the BRCA2 mutation. Reasoning by elimination, the finding of no elevated risk among BRCA2 mutation carriers and the dilution this likely had on the combined BRCA1 and BRCA2 analysis suggests that BRCA1 mutation carriers, in general, may be at greater risk of colorectal cancer. This quantitative finding is in contrast to the qualitative conclusion by Sopik et al. (17) of no increased risk in the population of BRCA1 mutation carriers at large, and the possible nearly fivefold risk in BRCA1-positive women younger than age 50 years.
There are some methodological differences between our study and the review by Sopik et al. (17) . We complemented their narrative review with both a systematic review and a set of omnibus and stratified meta-analyses. We categorized our 18 studies as cohort studies with ascertained BRCA mutation carriers (n ¼ 5), cohort studies involving pedigree analysis (n ¼ 6), case-control studies (n ¼ 5), cohort studies, and cohort studies involving kindred (n ¼ 2), of which 14 were included in the meta-analysis. Further, both reviews covered the same time period of about 20 years. However, our review included one study (21) published after the conclusion of the Sopik et al. (17) evaluations, but also an additional four studies (24) (25) (26) (27) released within the Sopik et al. 1994 Sopik et al. -2014 period. Of these five studies, four (21, (25) (26) (27) were entered into the meta-analysis. They carried moderate weight in the overall BRCA1 or BRCA2 meta-analyses, low weight in the BRCA1 subanalysis, and high weight in the BRCA2 subanalysis. This may have strengthened the evidence against a BRCA2 risk association with colorectal cancer. The lack of a statistically significant BRCA2 association may also have added to the finding of, at best, an equivocal association between general BRCA1 or BRCA2 mutation status and colorectal cancer risk. Importantly, the Mersch et al. (21) 2015 study in the BRCA1 subanalysis had a low relative weight in the metaanalysis that showed an increased in risk of colorectal cancer. This suggests that the studies included by Sopik et al. (17) in their review indeed would have yielded a statistically significant OR had these authors performed a meta-analysis.
Among the included studies, Brose et al. (28) and Thompson and Easton (11) had some duplication in terms of participants, but we included both the studies for three reasons. First of all, only 96 of 147 families included in Brose et al. are also used in the study by Thompson and Easton. Second, our study analyzed the presumed BRCA1 mutation carriers from the Brose et al. study. As to Thompson and Easton, our analyses included only 2245 tested BRCA1 mutation carriers, although the entire study included 11 847 participants. Therefore, all the presumed BRCA1 carriers in Thompson and Easton, duplicated in Brose et al., were not included in our analysis. Lastly, we conducted a sensitivity analysis by removing the Brose et al. study, and did not find a statistically significant difference. Therefore, we concluded that the overlap in the number of participants between Brose and Thompson in our analysis is relatively low, and included both of the studies.
Our meta-analysis has limitations and needs to be interpreted with some caution. Reviews hold the inherent risk of favoring some studies over others or some findings over others. First, heterogeneity in study designs must be acknowledged. Although most studies differentiated between BRCA1 and BRCA2 mutation carriers, some studies did not. Studies differed in how they ascertained BRCA mutation carriers with some studies defining mutation based on three well-known founder mutations, whereas other studies used whole-gene sequencing. Some studies did not confirm BRCA mutation by genetic testing but used pedigree instead, assuming that 50% of the study population would have BRCA mutations. Most studies focused on colorectal cancer, but three studies were limited to colon cancer. Due to the heterogeneity in study design, we performed subgroup analyses that, due to limited statistical power, did not permit stratification by BRCA mutation type or comparator. Only six studies were designed specifically to capture the risk of colorectal cancer in BRCA mutation carriers as their primary goal. The low incidence of colorectal cancers in some studies may be because these studies included several cancer types. Our stratified analyses carried with them the risk of limited statistical power, as the number of studies included in our analysis was small. Based on the NOS quality assessment results, all studies included in the meta-analysis were of moderate quality (NOS ¼ 4 to 6). Therefore, it was not feasible to conduct further analyses to assess heterogeneity by study quality. Second, all the studies reviewed were noncontrolled observational investigations that, consequently, may have been unbalanced with regard to baseline clinical and demographic characteristics of the subjects. Although the real-world practice may be better reflected in observational studies, the relative lack of baseline characteristics including risk factors make their interpretation more difficult and may induce bias. Family history, preexisting cancer, diet, smoking status, and increasing age are known risk factors for colorectal cancer (43) . Studies varied in the effect measure used, including SIR, RR, and OR, which necessitated some effect measures to be converted into ORs to make them useable in the meta-analyses.
In conclusion, where a previous qualitative review suggested an increased risk of early-onset colorectal cancer only in women under the age of 50 years carrying a BRCA1 mutation, our systematic review and meta-analysis points at a 1.49-fold greater risk of colorectal cancer in BRCA1 mutation carriers, but not in BRCA2 mutation carriers. Notes
